Fibroblast activation protein (FAP) has emerged as a promising molecular target for theranostic strategies. Here is a case of a 37-year-old woman with poorly differentiated pancreatic adenocarcinoma with lymph node metastasis who received 1 cycle of gemcitabine plus nab-paclitaxel, but relapsed a year ago. She then received 3 cycles of 177 Lu-FAP-2286 treatment, in combination with 6 cycles of gemcitabine plus nab-paclitaxel therapy. After that, the patient received an additional 2 cycles of 225 Ac-FAP-2286 treatment. A follow-up 68 Ga-FAP-2286 PET/CT scan revealed complete metabolic response of the lesions, and no severe adverse reactions were reported.
Tian et al. (Mon,) studied this question.